Ubiquitin D Polyclonal Antibody, PerCP Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-13006R-PerCP-100uL |
| Product Name | Ubiquitin D Polyclonal Antibody, PerCP Conjugated |
| Applications |
WB
|
| Reactivity | Human, Mouse |
| Predicted Reactivity | Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications | |
| Conjugation | PerCP |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human Ubiquitin D |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 10537 |
| Swiss Prot | O15205 |
| Subcellular location | Cytoplasm, Nucleus |
| Synonyms | FAT10; UBD-3; GABBR1; Ubiquitin D; Diubiquitin; Ubiquitin-like protein FAT10; UBD |
| Background | Ubiquitin-like protein modifier which can be covalently attached to target protein and subsequently leads to their degradation by the 26S proteasome, in a NUB1L-dependent manner. Probably functions as a survival factor. Conjugation ability activated by UBA6. Promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). Regulates TNF-alpha-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-alpha-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha. Required for TNF-alpha-induced p65 nuclear translocation in renal tubular epithelial cells (RTECs). May be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T-cell responses. Mediates mitotic non-disjunction and chromosome instability, in long-term in vitro culture and cancers, by abbreviating mitotic phase and impairing the kinetochore localization of MAD2L1 during the prometaphase stage of the cell cycle. May be involved in the formation of aggresomes when proteasome is saturated or impaired. Mediates apoptosis in a caspase-dependent manner, especially in renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN). |
| Application Dilution | |
| WB | 1:300-5000 |
Frequently asked questions
Which applications is Ubiquitin D Polyclonal Antibody, PerCP Conjugated (bs-13006R-PerCP) validated for, and at what dilution?
bs-13006R-PerCP is validated for WB (1:300-5000). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does Ubiquitin D Polyclonal Antibody, PerCP Conjugated (bs-13006R-PerCP) react with?
Tested reactivity: Human, Mouse. Predicted reactivity (expected from sequence homology but not yet tested): Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit.
How should bs-13006R-PerCP be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise Ubiquitin D Polyclonal Antibody, PerCP Conjugated (bs-13006R-PerCP)?
KLH conjugated synthetic peptide derived from human Ubiquitin D
What are the excitation and emission wavelengths of the PerCP conjugate (bs-13006R-PerCP)?
PerCP on bs-13006R-PerCP: excitation / emission 482nm/677nm.